BioXcel’s problem in 2025 was the gap between an approved medicine and a business able to finance itself. IGALMI had regulatory validation, but its small revenue base could not support the company’s development and operating commitments. That supported a financing-risk argument. It did not establish that the medicine had no value or that a particular commercial explanation was proven.
What the launch figures actually showed
For Q2 2025, BioXcel reported IGALMI revenue of $120,000, a $19.2 million net loss and $12.6 million of operating cash use. Its operating loss was $15.9 million, compared with $17.3 million a year earlier. The earlier quarter’s net loss had benefited from a $12 million derivative gain. These are different measures, so the increase in net loss did not demonstrate worsening operating performance on its own. BioXcel’s August 12 results provide the reconciliation.
The appropriate conclusion was narrower than “nobody is buying.” Sales were very small relative to the costs the company was carrying. A quarter of revenue also cannot reveal how much of the shortfall came from pricing, coverage, physician habits, sales resources or inventory timing. Those explanations require evidence of their own.
Cash use, financing and dilution
Cash, cash equivalents and restricted cash totaled $18.6 million at June 30. The same release disclosed subsequent gross proceeds of $11.5 million from share sales and $3.6 million from warrant exercises. Those amounts matter to a runway discussion; ignoring them overstates the immediacy of the cash constraint. They do not remove financing risk.
Annualizing one quarter’s operating cash use gives $50.4 million, while annualizing the net loss gives $76.8 million. Neither is a forecast. Trial costs, financing terms and commercial spending can change. A useful assessment asks how much unrestricted cash remains, what obligations fall due, and how much new capital is needed before the next milestone. Dilution depends on the amount raised and the price and terms of the securities issued; its magnitude cannot be calculated from the quarterly loss alone.
The at-home opportunity had a defined evidence boundary
IGALMI’s original FDA label covered acute agitation associated with schizophrenia or bipolar I or II disorder in adults under healthcare-provider supervision. Hypotension, bradycardia and somnolence were relevant safety considerations. Approval in that setting did not authorize unsupervised use at home.
On August 27, 2025, BioXcel reported that the 12-week SERENITY At-Home trial met its primary safety objective. It randomized 246 patients; 208 treated 2,437 episodes. The study evaluated 120 mcg, and efficacy findings were exploratory. The company then planned an sNDA submission in Q1 2026. The sponsor’s results announcement supported further regulatory review, not a guaranteed approval or launch date.
The commercial question would still remain after approval: whether an outpatient label, distribution model and payer coverage could produce sustained paid use. A favorable study cannot answer that question, but the weak institutional launch cannot prove the outpatient opportunity worthless either.
What happened later
BioXcel filed for Chapter 11 on August 27, 2026. Its October 30 Form 8-K reports that Teva acquired substantially all its neuroscience assets on October 26 for $57.5 million upfront plus contingent consideration. Sale proceeds were applied to debtor-in-possession financing obligations, with amounts retained for winding down the estates.
This outcome illustrates why the value of a medicine and the value of the original company’s equity must be evaluated separately. It does not repair the earlier article’s unsupported explanations by hindsight. The documented 2025 concern was a large financing requirement relative to commercial revenue; the later sale is a separate, observed event.
A related issue is how research spending changes reported earnings without proving a failed operating business. Our analysis of Biogen’s guidance bridge separates those effects.
